In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its ...
A groundbreaking international clinical trial has been testing an implanted adaptive deep brain stimulation (aDBS) device as ...
Acadia Pharmaceuticals Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally adopted a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results